Skip to main content
INCY
NASDAQ Life Sciences

Incyte口服皮肤药物Povorcitinib在晚期试验中提供强有力的长期症状缓解

feedReported by Reuters
Sentiment info
Positive
Importance info
9
Price
$90.3
Mkt Cap
$17.971B
52W Low
$53.56
52W High
$112.29
Market data snapshot near publication time

summarizeSummary

Incyte宣布其实验性口服皮肤疾病药物povorcitinib在中度至重度hidradenitis suppurativa（HS）患者的两项晚期试验中获得高度积极的长期数据。这些数据在医疗会议上发表，显示了多达71.4%的患者在54周后实现了至少50%的脓肿和炎症皮肤疼痛减少，一些患者实现了完全的病变清除。这对于Incyte来说是新的、重要的信息，因为作为JAK1抑制剂的povorcitinib已经被FDA和EMA审查。强效的疗效和口服制剂可能在选择有限的市场中对现有的注射性治疗（如AbbVie的Humira）提供显著的竞争优势。交易者将密切关注即将到来的监管决定。

在该公告发布时，INCY的交易价格为$90.30，交易所为NASDAQ，所属行业为Life Sciences，市值约为$179.7亿。 52周交易区间为$53.56至$112.29。 这则新闻被评估为积极市场情绪，重要性评分为9/10。 来源：Reuters。

show_chartPrice Chart

Share this article

Copied!

feed INCY - Latest Insights

INCY
Apr 28, 2026, 4:25 PM EDT
Filing Type: DEF 14A
Importance Score:
7
Incyte Details Strong 2025 Performance, Robust Pipeline, and Annual Meeting Proposals
Sentiment: Positive
View Wiseek Article
INCY
Apr 28, 2026, 4:02 PM EDT
Filing Type: 10-Q
Importance Score:
9
Incyte Reports Strong Q1 2026 Financials, Major Pipeline Progress, and Appoints New CFO
Sentiment: Positive
View Wiseek Article
INCY
Apr 28, 2026, 7:03 AM EDT
Filing Type: 8-K
Importance Score:
8
Incyte Reports Strong Q1 2026 Financial Results with 21% Revenue Growth and Positive Povorcitinib Phase 3 Data
Sentiment: Positive
View Wiseek Article
INCY
Mar 28, 2026, 3:00 PM EDT
Source: Reuters
Importance Score:
9
Incyte's Oral Skin Drug Povorcitinib Delivers Strong Long-Term Symptom Relief in Late-Stage Trials
Sentiment: Positive
View Wiseek Article
INCY
Mar 26, 2026, 8:38 AM EDT
Filing Type: 8-K
Importance Score:
7
Incyte Reorganizes Executive Leadership for Strategic Growth
Sentiment: Neutral
View Wiseek Article
INCY
Mar 06, 2026, 5:03 PM EST
Filing Type: 8-K
Importance Score:
7
FDA Issues Complete Response Letter for Zynyz in NSCLC Due to Manufacturing Site Issues
Sentiment: Negative
View Wiseek Article
INCY
Mar 06, 2026, 4:56 PM EST
Source: Reuters
Importance Score:
8
European Commission Approves Incyte's Zynyz for First-Line Advanced Anal Canal Cancer
Sentiment: Positive
View Wiseek Article
INCY
Feb 27, 2026, 9:23 AM EST
Source: Dow Jones Newswires
Importance Score:
7
EU Committee Backs Olumiant for Adolescent Alopecia Areata, Positive for Incyte
Sentiment: Positive
View Wiseek Article
INCY
Feb 10, 2026, 6:31 PM EST
Filing Type: SCHEDULE 13D/A
Importance Score:
8
Major Investor Baker Bros. Secures Rights to Sell 15.3% Stake in Incyte
Sentiment: Negative
View Wiseek Article
INCY
Feb 10, 2026, 4:01 PM EST
Filing Type: 10-K
Importance Score:
9
Incyte Reports Strong 2025 Financials, Major Pipeline Wins & Favorable Novartis Settlement
Sentiment: Positive
View Wiseek Article